NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s
Post# of 375
(Total Views: 159)
Posted On: 08/07/2023 4:36:00 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose last-known status remained cancer free as the current trial process began ahead of the COVID-19 pandemic,” a recent article reads. “CNS Pharmaceuticals has raised sufficient capital to enable the company to secure its trial beyond the interim analysis at least into the fourth quarter. Primary completion of the trial is expected next year, with final results in late 2024 or early 2025. The trial has achieved global status, recruiting patients in the United States, Spain, France, Switzerland and Italy.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose last-known status remained cancer free as the current trial process began ahead of the COVID-19 pandemic,” a recent article reads. “CNS Pharmaceuticals has raised sufficient capital to enable the company to secure its trial beyond the interim analysis at least into the fourth quarter. Primary completion of the trial is expected next year, with final results in late 2024 or early 2025. The trial has achieved global status, recruiting patients in the United States, Spain, France, Switzerland and Italy.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)